Trial Profile
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-2 (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 29 Mar 2021 Status changed from active, no longer recruiting to completed.
- 10 Jan 2021 Planned End Date changed from 1 Oct 2020 to 1 Feb 2021.
- 14 May 2019 Planned End Date changed from 11 Sep 2020 to 1 Oct 2020.